NRIX
NASDAQNurix Therapeutics Inc.
News · 26 weeks62+267%
2026-04-192026-10-11
Mix2790d
- Insider12(44%)
- Other11(41%)
- SEC Filings3(11%)
- Leadership1(4%)
Latest news
25 items- INSIDERSEC Form 4 filed by Nurix Therapeutics Inc.4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- SECSEC Form 144 filed by Nurix Therapeutics Inc.144 - Nurix Therapeutics, Inc. (0001549595) (Subject)
- INSIDERSEC Form 4 filed by Nurix Therapeutics Inc.4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- SECSEC Form 10-Q filed by Nurix Therapeutics Inc.10-Q - Nurix Therapeutics, Inc. (0001549595) (Filer)
- SECSEC Form 8-K filed by Nurix Therapeutics Inc.8-K - Nurix Therapeutics, Inc. (0001549595) (Filer)
- PRNurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateDosed first patient in registrational Phase 3 DAYBreak CLL-306 trial comparing bexobrutideg with pirtobrutinib in relapsed/refractory CLL/SLL Advanced bexobrutideg combination strategy with initiation of recruiting for the Phase 1b/2 NX-5948-203 study Earned $27M from Gilead, Pfizer and Sanofi collaborations, including a $10M milestone from Sanofi for first patient dosed in the STAT6 degrader Phase 1 trial Advanced NX-1607 into Phase 1b expansion cohorts in MSS CRC, NSCLC, CRPC and melanoma with the first patient dosed in September 2026 Following receipt of the $700 million upfront as part of the close of the Roche collaboration, Nurix has $1.1 billion in cash, cash equivalents and mark
- PRNurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic LeukemiaFirst patient enrolled in cohort combining bexobrutideg with venetoclax Initial cohort to focus on relapsed/refractory CLL, with potential expansion to first-line CLL Strategy includes evaluation of bexobrutideg given in combination with venetoclax and selected antibodies in the Roche portfolio of B-cell malignancy therapies BRISBANE, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX) today announced that the first patient has been enrolled in the Phase 1b/2 NX-5948-203 study evaluating bexobrutideg, an investigational oral Bruton’s tyrosine kinase (BTK) degrader, in combination with venetoclax, a standard-of-care therapy for patients with chronic lymphocy
- PRNurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead SciencesTwo-year extension builds on productive relationship established in 2019 Nurix continues to retain co-development and 50/50 profit sharing options on up to two programs in the United States BRISBANE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that Nurix and Gilead Sciences have agreed to extend the research term for an undisclosed oncology program within the companies’ ongoing strategic collaboration by an additional two years. This is the second two-year extension of the research term for
- INSIDERChief Legal Officer Ring Christine exercised 5,786 shares at a strike of $8.72 and sold $134,149 worth of shares (5,786 units at $23.19) as part of a pre-agreed trading plan (SEC Form 4)4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- PRNurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with PfizerBRISBANE, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced the achievement of a $7 million research milestone under its strategic collaboration with Pfizer for the discovery and development of degrader antibody conjugates (DACs). Nurix entered into the collaboration with Seagen Inc., now part of Pfizer, in September 2023. Under the terms of the agreement, Nurix received an upfront payment of $60 million and became eligible to receive up to $3.4 billion in potential research, development, regulato
- SECSEC Form SCHEDULE 13G filed by Nurix Therapeutics Inc.SCHEDULE 13G - Nurix Therapeutics, Inc. (0001549595) (Subject)
- INSIDERChief Legal Officer Ring Christine exercised 5,787 shares at a strike of $8.72 and sold $149,072 worth of shares (5,787 units at $25.76) as part of a pre-agreed trading plan (SEC Form 4)4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- INSIDERChief Scientific Officer Hansen Gwenn exercised 1,452 shares at a strike of $1.86 and sold $36,982 worth of shares (1,452 units at $25.47) as part of a pre-agreed trading plan (SEC Form 4)4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- PRNurix Therapeutics to Participate in Upcoming September Investor ConferencesBRISBANE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that Company management will participate in fireside chats at the following investor conferences: Wells Fargo Healthcare ConferenceTuesday, September 8, 2026, at 3:00 p.m. ETH.C. Wainwright Healthcare ConferenceMonday, September 14, 2026, at 1:00 p.m. E.TBaird Healthcare ConferenceTuesday, September 15, 2026, at 3:10 p.m. ETMorgan Stanley Healthcare ConferenceWednesday, September 16, 2026, at 7:45 a.m. ET The fireside chats will be webca
- PRNurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources OfficerBRISBANE, Calif., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company developing targeted protein degradation medicines for patients with cancer and inflammatory diseases, today announced that Wes Burwell has joined Nurix as its Chief Human Resources Officer (CHRO). Mr. Burwell will serve as a member of the company’s Executive Management Team and will lead Nurix's human resources organization as the company advances its late-stage clinical pipeline and prepares for commercialization while maintaining its leadership position in targeted protein degradation drug discovery research. "Nurix is entering a new chapter as we evolve
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Nurix Therapeutics Inc.SCHEDULE 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)
- SECSEC Form SCHEDULE 13G filed by Nurix Therapeutics Inc.SCHEDULE 13G - Nurix Therapeutics, Inc. (0001549595) (Subject)
- INSIDERChief Scientific Officer Hansen Gwenn exercised 4,356 shares at a strike of $1.86 and sold $108,900 worth of shares (4,356 units at $25.00) as part of a pre-agreed trading plan (SEC Form 4)4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- INSIDERChief Scientific Officer Hansen Gwenn sold $100,142 worth of shares (4,111 units at $24.36) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 117,227 units (SEC Form 4)4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- INSIDERChief Financial Officer Van Houte Hans sold $115,989 worth of shares (4,761 units at $24.36) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 40,166 units (SEC Form 4)4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- PRNurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 DegraderOral STAT6 degrader advances into clinical development for type 2 inflammatory diseases Nurix has earned approximately $139 million to date under its collaboration with Sanofi and remains eligible to receive approximately $453 million in future milestones associated with the STAT6 program, as well as potential royalties, and retains a U.S. co-development and co-promotion option BRISBANE, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that it has earned a $10 million milestone payment following
- PRNurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaBRISBANE, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX) today announced that the first patient has been enrolled in the global Phase 3 DAYBreak CLL-306 study (NCT07516093) evaluating bexobrutideg, a potential best-in-class targeted protein degrader of Bruton’s tyrosine kinase (BTK), in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received a covalent BTK inhibitor. The global study is being conducted under the collaboration between Nurix and Roche and marks the first Phase 3 trial for bexobrutideg. The registrational study is designed to demonstrate the superiority of bexobrutideg v
- INSIDERChief Legal Officer Ring Christine exercised 5,787 shares at a strike of $8.72 and sold $382,358 worth of shares (16,589 units at $23.05) as part of a pre-agreed trading plan, decreasing direct ownership by 54% to 9,110 units (SEC Form 4)4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- INSIDERChief Financial Officer Van Houte Hans converted options into 10,180 shares and sold $66,524 worth of shares (2,845 units at $23.38), increasing direct ownership by 20% to 44,927 units (SEC Form 4) (withholding obligation)4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- INSIDERChief Legal Officer Ring Christine converted options into 10,180 shares and sold $89,954 worth of shares (3,847 units at $23.38), increasing direct ownership by 47% to 19,912 units (SEC Form 4) (tax liability)4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
NRIX FAQ
7 questionsWhat does Nurix Therapeutics Inc. do?
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader with immunomodulatory drug (IMiD) activity for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader without IMiD activity for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally available Casitas B-lineage lymphoma...Where does NRIX stock trade?
Nurix Therapeutics Inc. (NRIX) is listed on NASDAQ.What sector and industry is NRIX in?
Nurix Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Nurix Therapeutics Inc. go public?
Nurix Therapeutics Inc. (NRIX) completed its IPO in 2020.What are analysts saying about NRIX?
Nurix Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Oppenheimer: Outperform with a $2800.00 price target on 2026-06-29. Recent price targets range from $1600.00 to $3600.00.What companies are similar to NRIX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare NRIX side-by-side with any of them on Quantisnow.How can I track NRIX on Quantisnow?
Quantisnow aggregates Nurix Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NRIX to receive live email and push alerts on every new disclosure.